JP2019517482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517482A5 JP2019517482A5 JP2018562172A JP2018562172A JP2019517482A5 JP 2019517482 A5 JP2019517482 A5 JP 2019517482A5 JP 2018562172 A JP2018562172 A JP 2018562172A JP 2018562172 A JP2018562172 A JP 2018562172A JP 2019517482 A5 JP2019517482 A5 JP 2019517482A5
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- composition
- effective amount
- administered
- citrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 18
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims 10
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 7
- 230000001225 therapeutic effect Effects 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 5
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 5
- 235000019158 vitamin B6 Nutrition 0.000 claims 5
- 239000011726 vitamin B6 Substances 0.000 claims 5
- 229940011671 vitamin b6 Drugs 0.000 claims 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 4
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims 4
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims 4
- 239000011575 calcium Substances 0.000 claims 4
- 229910052791 calcium Inorganic materials 0.000 claims 4
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims 4
- 235000016709 nutrition Nutrition 0.000 claims 4
- 235000019175 phylloquinone Nutrition 0.000 claims 4
- 239000011772 phylloquinone Substances 0.000 claims 4
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims 4
- 229960001898 phytomenadione Drugs 0.000 claims 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 3
- 206010020590 Hypercalciuria Diseases 0.000 claims 3
- 206010029148 Nephrolithiasis Diseases 0.000 claims 3
- 229930003448 Vitamin K Natural products 0.000 claims 3
- 239000000395 magnesium oxide Substances 0.000 claims 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims 3
- 235000019168 vitamin K Nutrition 0.000 claims 3
- 239000011712 vitamin K Substances 0.000 claims 3
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 3
- 235000019143 vitamin K2 Nutrition 0.000 claims 3
- 239000011728 vitamin K2 Substances 0.000 claims 3
- 229940046010 vitamin k Drugs 0.000 claims 3
- 150000001860 citric acid derivatives Chemical class 0.000 claims 2
- 239000004337 magnesium citrate Substances 0.000 claims 2
- 235000002538 magnesium citrate Nutrition 0.000 claims 2
- 229960005336 magnesium citrate Drugs 0.000 claims 2
- 239000001508 potassium citrate Substances 0.000 claims 2
- 229960002635 potassium citrate Drugs 0.000 claims 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims 2
- 235000011082 potassium citrates Nutrition 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229960003975 potassium Drugs 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022124960A JP2022153651A (ja) | 2016-06-02 | 2022-08-04 | 高カルシウム尿症及び腎結石症の治療方法及び治療用組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344653P | 2016-06-02 | 2016-06-02 | |
| US62/344,653 | 2016-06-02 | ||
| PCT/US2017/035514 WO2017210467A1 (en) | 2016-06-02 | 2017-06-01 | Methods and compositions for treatment of hypercalciuria and nephrolithiasis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022124960A Division JP2022153651A (ja) | 2016-06-02 | 2022-08-04 | 高カルシウム尿症及び腎結石症の治療方法及び治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517482A JP2019517482A (ja) | 2019-06-24 |
| JP2019517482A5 true JP2019517482A5 (enExample) | 2020-07-16 |
Family
ID=60479095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018562172A Pending JP2019517482A (ja) | 2016-06-02 | 2017-06-01 | 高カルシウム尿症及び腎結石症の治療方法及び治療用組成物 |
| JP2022124960A Withdrawn JP2022153651A (ja) | 2016-06-02 | 2022-08-04 | 高カルシウム尿症及び腎結石症の治療方法及び治療用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022124960A Withdrawn JP2022153651A (ja) | 2016-06-02 | 2022-08-04 | 高カルシウム尿症及び腎結石症の治療方法及び治療用組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200315233A1 (enExample) |
| EP (1) | EP3463322A4 (enExample) |
| JP (2) | JP2019517482A (enExample) |
| AU (1) | AU2017274438A1 (enExample) |
| BR (1) | BR112018075067A2 (enExample) |
| CA (1) | CA3026143A1 (enExample) |
| CO (1) | CO2018013999A2 (enExample) |
| CR (1) | CR20180576A (enExample) |
| DO (1) | DOP2018000265A (enExample) |
| EC (1) | ECSP19000167A (enExample) |
| MX (2) | MX2018014933A (enExample) |
| NI (1) | NI201800126A (enExample) |
| TW (1) | TW201808271A (enExample) |
| WO (1) | WO2017210467A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109806225B (zh) * | 2019-03-16 | 2021-06-01 | 西安安健药业有限公司 | 维生素k1脂肪乳注射液 |
| CN112438967A (zh) * | 2019-08-27 | 2021-03-05 | 高兵 | 维生素k在制备泌尿系结石防治药物和保健品中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4446024C2 (de) * | 1994-12-22 | 1997-01-23 | Bartz Volker | Verwendung eines Vitamins der K-Gruppe |
| GT199800126A (es) * | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| CN1322530A (zh) * | 2000-05-09 | 2001-11-21 | 詹炳炎 | 一种防治泌尿系结石的药物——尿石净 |
| EP1411951B2 (en) * | 2001-07-27 | 2010-11-10 | N.V. Nutricia | Enteral compositions for the prevention and/or treatment of sepsis |
| US20050233461A1 (en) * | 2002-06-05 | 2005-10-20 | Douglas Levinson | High-throughput methods and systems for screening of compounds to treat/prevent kidney disorders |
| US8703209B2 (en) * | 2003-06-17 | 2014-04-22 | Edward Larry McCleary | Composition and method for modulating hydrogen ion physiology |
| US20080220094A1 (en) * | 2006-11-01 | 2008-09-11 | Wyeth | Compositions and methods for the treatment and/or prevention of osteoporosis |
| AU2008322224B2 (en) * | 2007-07-24 | 2012-05-10 | Synergia Life Sciences Pvt Limited | Treatments using vitamin K analogues and derivatives |
| JP2013504572A (ja) * | 2009-09-14 | 2013-02-07 | ネステク ソシエテ アノニム | 外因性ビタミンｋ２を含む炎症調節用栄養組成物 |
| US20110229587A1 (en) * | 2009-09-24 | 2011-09-22 | Algaecal Distribution Inc. | Calcium Supplements for the Treatment of Diabetes |
| US20140031432A1 (en) * | 2010-08-06 | 2014-01-30 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
| WO2012170773A1 (en) * | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| US20150359807A1 (en) * | 2014-06-11 | 2015-12-17 | Supernutrition Life-Extension Research, Inc. | Dietary Supplement Containing Vitamin A, D3 and Vitamin K2 and Uses Thereof |
-
2017
- 2017-06-01 WO PCT/US2017/035514 patent/WO2017210467A1/en not_active Ceased
- 2017-06-01 CR CR20180576A patent/CR20180576A/es unknown
- 2017-06-01 JP JP2018562172A patent/JP2019517482A/ja active Pending
- 2017-06-01 AU AU2017274438A patent/AU2017274438A1/en not_active Abandoned
- 2017-06-01 US US16/305,040 patent/US20200315233A1/en active Pending
- 2017-06-01 CA CA3026143A patent/CA3026143A1/en active Pending
- 2017-06-01 EP EP17807504.0A patent/EP3463322A4/en not_active Withdrawn
- 2017-06-01 MX MX2018014933A patent/MX2018014933A/es unknown
- 2017-06-01 BR BR112018075067-0A patent/BR112018075067A2/pt not_active IP Right Cessation
- 2017-06-02 TW TW106118261A patent/TW201808271A/zh unknown
-
2018
- 2018-11-30 NI NI201800126A patent/NI201800126A/es unknown
- 2018-11-30 MX MX2022013681A patent/MX2022013681A/es unknown
- 2018-12-03 DO DO2018000265A patent/DOP2018000265A/es unknown
- 2018-12-21 CO CONC2018/0013999A patent/CO2018013999A2/es unknown
-
2019
- 2019-01-02 EC ECSENADI2019167A patent/ECSP19000167A/es unknown
-
2022
- 2022-08-04 JP JP2022124960A patent/JP2022153651A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0520082A2 (pt) | formas de dosagem de risedronato | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| ES2982123T3 (es) | Agente para la inmunomodulación de apoyo que contiene ácido propiónico y éster de ácido fumárico | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| JP2009541348A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JP6063550B2 (ja) | 薬物誘発性手足症候群を治療するための組成物および方法 | |
| JP2008509224A5 (enExample) | ||
| JP2017503761A5 (enExample) | ||
| JP2014221827A5 (enExample) | ||
| JP2016535780A5 (enExample) | ||
| JP2019517482A5 (enExample) | ||
| BR112016017765A8 (pt) | composição compreendendo cinamaldeído e zinco, seu uso, e método para produzir um produto alimentício para perda de peso | |
| HRP20211488T1 (hr) | Sastav i metoda za liječenje metaboličkih poremećaja | |
| JP2017061488A5 (enExample) | ||
| MX2022013681A (es) | Metodos y composiciones para el tratamiento de la hipercalciuria y la nefrolitiasis. | |
| WO2014142760A3 (en) | Re-trafficking of herg reverses long qt syndrome 2 phenotype in human ips-derived cardiomyocytes | |
| JP2012041314A5 (enExample) | ||
| Nikitin et al. | Cholelithiasis: epidemiological data, key aspects of the pathogenesis and comorbidity, relevant therapeutic targets | |
| JP2016525530A5 (enExample) | ||
| BR112012011316A2 (pt) | tivozanib e temsirolimus em combinação | |
| Bifulco | Antibiotics exposure in obesity: an update of a complex relationship | |
| JP2016514142A5 (enExample) | ||
| Aukerman | Do vitamin C supplements reduce cardiovascular disease mortality? | |
| Di Mitri et al. | P. 1.329: ENDOSCOPIC PLACEMENT OF SELF-EXPANDABLE METAL STENTS FOR MALIGNANT COLONIC OBSTRUCTION: A REGIONAL MULTICENTER EXPERIENCE IN A LARGE COHORT OF TREATED PATIENTS |